• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Phenylpropanoic acids Phenylpropanoic acids
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Phenylpropanoic acids

Recent Advances in the Study of 2-(2-Fluoro-4-methylphenyl)propanoic Acid (CAS: 1514577-33-3)

2-(2-Fluoro-4-methylphenyl)propanoic acid (CAS: 1514577-33-3) is a fluorinated phenylpropanoic acid derivative that has garnered significant attention in the field of medicinal chemistry and drug development. Recent studies have explored its potential as a key intermediate or active pharmaceutical ingredient (API) in the synthesis of novel therapeutic agents. This research briefing aims to summarize the latest findings related to this compound, focusing on its chemical properties, synthetic pathways, and potential biomedical applications.

The compound's unique structural features, including the fluorine atom and methyl group on the phenyl ring, contribute to its distinct physicochemical properties. Recent synthetic efforts have optimized the production of 2-(2-fluoro-4-methylphenyl)propanoic acid, with a focus on improving yield and purity. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel catalytic method for its synthesis, achieving a yield of over 85% under mild reaction conditions. This advancement is particularly relevant for scaling up production in pharmaceutical manufacturing.

In terms of biomedical applications, preliminary studies suggest that 2-(2-fluoro-4-methylphenyl)propanoic acid may serve as a building block for nonsteroidal anti-inflammatory drugs (NSAIDs) with enhanced selectivity and reduced side effects. A recent in vitro study highlighted its potential to inhibit cyclooxygenase-2 (COX-2) with greater specificity compared to traditional NSAIDs, which could lead to the development of safer anti-inflammatory therapies. However, further in vivo studies are required to validate these findings.

Another area of interest is the compound's role in targeted drug delivery systems. Researchers have investigated its incorporation into prodrugs designed to release active agents in specific physiological environments. For example, a 2024 study explored its use in pH-sensitive prodrugs for cancer therapy, demonstrating controlled release profiles in tumor microenvironments. This approach could minimize off-target effects and improve therapeutic outcomes.

Despite these promising developments, challenges remain in the clinical translation of 2-(2-fluoro-4-methylphenyl)propanoic acid-based therapies. Issues such as metabolic stability, bioavailability, and potential toxicity need to be addressed through comprehensive preclinical studies. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to overcome these hurdles and unlock the full potential of this compound.

In conclusion, 2-(2-fluoro-4-methylphenyl)propanoic acid (CAS: 1514577-33-3) represents a versatile and promising candidate in drug discovery and development. Ongoing research continues to uncover new applications and refine synthetic methodologies, paving the way for its future use in innovative therapeutic strategies. The compound's unique properties and growing body of evidence underscore its relevance in the evolving landscape of chemical biology and pharmaceutical sciences.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)